Nulojix

Active Ingredient(s): Belatacept
FDA Approved: * June 15, 2011
Pharm Company: * BRISTOL MYERS SQUIBB
Category: Immunosuppressive

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineur... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nulojix 250 mg/1 Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0003-0371
Labeler:
E.r. Squibb & Sons, L.L.C.